Heghine Khachatryan on a UK Milestone: National CYP2C19 Testing Before Clopidogrel Therapy
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post by Lydia Kariuki on LinkedIn:
“Precision medicine in action: a milestone for antiplatelet therapy
The UK has taken a significant step toward truly personalized cardiovascular care by recommending routine CYP2C19 pharmacogenetic testing before initiating clopidogrel therapy within the NHS.
Clopidogrel remains a cornerstone antiplatelet agent for patients with coronary, cerebrovascular, and peripheral arterial disease. However, its clinical efficacy is highly dependent on CYP2C19-mediated bioactivation, leading to substantial inter-individual variability in response.
This national pharmacogenomic recommendation directly addresses a long-standing clinical challenge:
- reduced efficacy in CYP2C19 loss-of-function carriers
- preventable thrombotic events
- avoidable trial-and-error prescribing
Implementing PGx testing before treatment initiation allows clinicians to:
- identify non-responders early
- select alternative antiplatelet agents when appropriate
- improve outcomes while reducing complications
This is a powerful example of how pharmacogenomics can be translated into real-world clinical practice at a national level.
For countries and health systems striving to modernize cardiovascular care, this sets an important benchmark.
Precision medicine is no longer the future — it is becoming standard of care.”
Quoting Lydia Kariuki’s post:
“CYP2C19 pharmacogenetic (PGx) testing for all patients in the UK before prescribing clopidogrel
The UK has taken a major step forward in precision prescribing with the publication of its first national pharmacogenomic guideline, focused on the antiplatelet drug clopidogrel.
Clopidogrel is widely prescribed across the NHS to prevent blood clots in patients with coronary artery disease, cerebrovascular disease, and peripheral arterial disease. But while the medication is standard therapy, its effectiveness varies substantially between individuals. The new guideline directly addresses this variability by recommending CYP2C19 genotyping for patients before clopidogrel therapy is initiated.”
Stay updated and find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Oct 13, 2026, 15:51Merel Timmer: Hemophilia Twinning Partnership Strengthens Care and Quality of Life in Indonesia
-
Oct 13, 2026, 15:41Sarah Alam: ASH 2026 Guidelines on Iron Deficiency Diagnosis and Updated Ferritin Thresholds
-
Oct 13, 2026, 15:35Jamie Elmawieh: Prophylactic Anticoagulation Improves Survival in Isolated Tumor Thrombus
-
Oct 13, 2026, 15:30Sally Mandour: Methemoglobinemia When Hemoglobin Cannot Carry Oxygen
-
Oct 13, 2026, 15:21Renel Tique: Advancing Hemophilia Care Through Global Collaboration and Clinical Innovation
-
Oct 13, 2026, 15:08Anastasia Chatzistamati: Unilateral Adrenal Haemorrhage in Primary Antiphospholipid Syndrome
-
Oct 13, 2026, 15:08Yousma Khan: Hematology Practical Series Day 11 Reticulocyte Count and Its Role in Anemia Diagnosis
-
Oct 13, 2026, 14:56Manal Rayyan: Multidisciplinary Collaboration in Rare Bleeding Disorders – Reflections from Abu Dhabi
-
Oct 13, 2026, 14:54Kalyan Roy: Understanding Blood Transfusion Sets for Safe Clinical Administration